Naringenin surveillance study was conducted between January , and February , at centers worldwide . This was an observational study because the protocol required no intervention in the treatme manageme and/or behavior of the patients. The protocol merely required observations to be reported that would be available as a result of norm noninterventional medical practice. Therefo patients were not participants in this stu Table . Distribution of patients by country. preferred because simplification of treatment carries the advantage of betterpliance with therapy .
Other international guidelin such as those put forth by Canadian and Russian exper Piroxicam similarly endorse a preference for single-pillbinations whenbination therapy is required. Suchbinations may be particularly beneficial as first-line therapy in high-risk patien in whom more rapid and pronounced BP control is desired. Country Russia Middle East countries Philippines Saudi Arabia Thailand India Total Patients enroll Patients analyz only subjects of observation. In accordance with the definition of ?noninterventionstudie therapy was prescribed in terms of the marketing authorization.
The assignment of patient to therapy was decided within the current practice and medical indicati and was separated from the decision to include the patient in the study. The dose of single-pillbination amlodipine/valsartan prescribed by the treating physician was purchase Phloretin recorded at the initial visit. After enrolment in the stu patients did not undergo any special change in dietary habi medicati lifesty or exercise schedule. Coitant medicatio including antihypertensive dru were allowed in the study at the discretion of the treating physician. Patients were observed over a -month period with approximately monthly intervals between clinic visit which were not fix but adhered to themon practice in this indication.
Patients could discontinue participation in the study for any reason. In the event of order Elesclomol premature terminati the date and reason for discontinuation were documented. Patients The eligible population consisted of men and women years of age with arterial hypertension for whom antihypertensive therapy with thebination of amlodipine and valsartan and mg daily was indicated. These are the rmended doses for the treatment of arterial hypertension according to the Summary of Product Characteristics for Exe . Single-pillbination therapy with amlodipine/valsartan at doses of either or mg once daily was subsequently prescribed to the patient by the treating physician. Adv Ther . In countries where local regulations required approval from an Independent Ethicsmitt approval was obtained before the study was initiated.
It was the responsibility of the treating physician to obtain the patient oral or written informed consent and to report his/her medical data anonymously to Novartis Phar in order to analyze and publish them. Patients were not eligible for the study if they were women who were pregna intended to be pregna or were breastfeeding; had known carbohydrates hypersensitivity to amlodipine/valsartan or any excipients in the formulation; or had a severe medical condition th in the opinion of the investigat prohibited participation in the study . Evaluations At the initial study visi demographic informati relevant medical.